NODES_INNDIANA_Z120_Very Low Energy Ketogenic Therapy improves MASLD and Metabolic Dysfunction in patients with Type 2 Diabetes and Obesity
Fuente:
Zenodo
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | Recurso digital |
| Langue: | anglais |
| Publié: |
Zenodo
2026
|
| Sujets: | |
| Accès en ligne: | |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| _version_ | 1866901878491578368 |
|---|---|
| author | Celano, Stefano Tini, Sabrina Prodam, Flavia |
| author_facet | Celano, Stefano Tini, Sabrina Prodam, Flavia |
| contents | <p>"Obesity and Type 2 Diabetes (T2D) are major public health issues, associated with several comorbidities and increased mortality worldwide. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has emerged as the most prevalent form of chronic liver disease closely related to both obesity and T2D. The ketogenic diet, referred to as a Very Low Energy Ketogenic Therapy (VLEKT), is increasingly applied in clinical setting for its effectiveness in promoting weight loss. It has also shown promise in reducing hepatic<br>fat accumulation and fibrosis. However, the effects of VLEKT on glucometabolic parameters<br>remained to be fully clarified. Aim: This 12-weeks pilot study aimed to evaluate the efficacy of the VLEKT on body composition, glucometabolic and liver parameters in obese subjects diagnosed with T2D and MASLD."</p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_18630367 |
| institution | Zenodo |
| language | eng |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | NODES_INNDIANA_Z120_Very Low Energy Ketogenic Therapy improves MASLD and Metabolic Dysfunction in patients with Type 2 Diabetes and Obesity Celano, Stefano Tini, Sabrina Prodam, Flavia Spoke 5 - Industry for Health and Silver Economy INNDIANA Project Eco healthcare ECS00000036 Ketogenic Diet weight loss obesity diabetes <p>"Obesity and Type 2 Diabetes (T2D) are major public health issues, associated with several comorbidities and increased mortality worldwide. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has emerged as the most prevalent form of chronic liver disease closely related to both obesity and T2D. The ketogenic diet, referred to as a Very Low Energy Ketogenic Therapy (VLEKT), is increasingly applied in clinical setting for its effectiveness in promoting weight loss. It has also shown promise in reducing hepatic<br>fat accumulation and fibrosis. However, the effects of VLEKT on glucometabolic parameters<br>remained to be fully clarified. Aim: This 12-weeks pilot study aimed to evaluate the efficacy of the VLEKT on body composition, glucometabolic and liver parameters in obese subjects diagnosed with T2D and MASLD."</p> |
| title | NODES_INNDIANA_Z120_Very Low Energy Ketogenic Therapy improves MASLD and Metabolic Dysfunction in patients with Type 2 Diabetes and Obesity |
| topic | Spoke 5 - Industry for Health and Silver Economy INNDIANA Project Eco healthcare ECS00000036 Ketogenic Diet weight loss obesity diabetes |
| url | https://doi.org/10.5281/zenodo.18630367 |